Safety and efficacy of ferric carboxymaltose in management of iron deficiency anemia in pregnant and peripartum women

Divyang S. Bhudhrani; Payal Godria

doi:10.18203/2320-1770.ijrcog20242057

Authors

Divyang S. Bhudhrani Department of Internal Medicine, Bukovinian State Medical University, Teatral'na Square, Chernivtsi, Chernivets'ka Oblast, Ukraine
Payal Godria Department of Obstetrics and Gynaecology, M. S. University, Baroda, Gujarat, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242057

Keywords:

Ferric carboxymaltose, Iron deficiency anemia, Pregnant women

Abstract

Background: Anemia during pregnancy, often attributed to iron deficiency, poses substantial risks to both maternal and fetal health. This retrospective study aims to evaluate the safety and efficacy of intravenous ferric carboxymaltose (FCM) in managing anemia among pregnant women.

Methods: The study encompasses women who received FCM treatment for anemia during pregnancy between October 2023 and March 2024 at SSG hospital, Vadodara. Key outcomes evaluated include maternal safety and pregnancy outcomes. Prospective observational study; Treatment effectiveness was assessed by repeat hemoglobin (Hb) measurements and patient report of well-being in the postpartum period. Safety was assessed by analysis of adverse drug reactions and fetal heart rate monitoring during the infusion.

Results: A total of 50 patients were included. The intravenous administration of FCM notably raised hemoglobin levels in all pregnant female participants compared to initial levels. Monitoring of fetal heart rate showed no adverse effects attributable to the medication. No severe side effects were observed.

Conclusions: This prospective observational study suggests that FCM represents a safe and effective therapeutic option for managing anemia during pregnancy. Despite study limitations, the findings underscore the potential of FCM in addressing this prevalent concern, advocating for its consideration in clinical practice.

Metrics

Metrics Loading ...

References

International Institute for Population Sciences (IIPS). National Family Health Survey (NFHS-4), 2015-16, 2017. Available at: https://dhsprogram.com/pubs/pdf/FR339/FR339.pdf. Accessed 01 April 2024.

Pasricha, sant-rayn, et al. "prevalence of iron deficiency in pregnant women in india: a systematic review with meta-analysis." Ind J Med Res. 2020;151(5):437-47.

Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol. 2008;87(12):949-59.

Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156(5):588-600.

Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet. 2010;282(5):577-80.

Scholl TO, Hediger ML, Fischer RL, Shearer JW. Anemia vs iron deficiency: increased risk of preterm delivery in a prospective study. Am J Clin Nutr. 1992;55(5):985-8.

Zhang Q, Ananth CV, Li Z, Smulian JC. Maternal anaemia and preterm birth: a prospective cohort study. Int J Epidemiol. 2009;38(5):1380-9.

Allen LH. Anemia and iron deficiency: effects on pregnancy outcome. Am J Clin Nutr. 2000;71(5 Suppl):1280S-4S.

Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005;81(5):1218S-22S.

Pena-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;(10):CD009997.

Gupta PM, Perrine CG, Mei Z, Scanlon KS. Iron, anemia, and iron deficiency anemia among young children in the United States. Nutrients. 2016;8(6):330.

Muñoz M, Gómez-Ramírez S, Besser M, Pavía J, Gomollón F, Liumbruno GM, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017;15(5):422-37.

Milman N. Anemia-still a major health problem in many parts of the world! Ann Hematol. 2011;90(4):369-77.

Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222-7.

Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83-92.

Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2015;75(1):101-27.

European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) [EMA/CHMP/BPWP/94033/2007 Rev. 2], 2021. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-revision-2_en.pdf. Accessed 16 April 2024.

Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res. 2007;30(1):15-30.

Macdougall IC, Vernon K, Comin-Colet J. Benefits and risks of intravenous iron therapy in chronic kidney disease. Expert Opin Drug Saf. 2016;15(2):265-78.

Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular, and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant. 2010;25(12):3631-40.

Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Biol Trace Elem Res. 2009;129(1-3):69-78.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.

Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-68.

Rodighiero MP, De Marchi S, Riva A. Short- and long-term effects of intravenous iron supplementation in chronic heart failure patients with iron deficiency: the IRON-HF study. Int J Cardiol. 2016;212:306-12.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J. 2015;36(11):657-668.

Rodighiero MP, De Marchi S, Riva A, et al. Short- and long-term effects of intravenous iron supplementation in chronic heart failure patients with iron deficiency: the IRON-HF study. Int J Cardiol. 2016;212:306-312. doi:10.1016/j.ijcard.2016.03.051

Muñoz M, Gómez-Ramírez S, Besser M, Pavía J, Gomollón F, Liumbruno GM, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017;15(5):422-37.

Milman N. Anemia-still a major health problem in many parts of the world! Ann Hematol. 2011;90(4):369-377.

Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood. 2011;118(12):3222-7.

Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83-92.

Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2015;75(1):101-27.